What the FDA labels say about taking them together
Allopurinol and nelarabine
Nelarabine's FDA label of March 31, 2025 names allopurinol in its warnings and precautions section; the allopurinol labels PlainMeds reads (4) do not name nelarabine. The nelarabine label: “Consideration should be given to the use of allopurinol in patients at risk of hyperuricemia.”
Check it at the source: the allopurinol FDA label on DailyMed (effective May 21, 2026, Rising Pharma Holdings, Inc.); the nelarabine FDA label on DailyMed (effective March 31, 2025, Sandoz Inc).
What does the allopurinol label say about nelarabine?
Allopurinol's label (effective May 21, 2026) and its 3 other brand-application labels do not name nelarabine in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Allopurinol), Rising Pharma Holdings, Inc., effective May 21, 2026 (SPL set 30ad5ba2-1cef-4933-b104-0597f6a2aaa2), via openFDA; the full label on DailyMed
What does the nelarabine label say about allopurinol?
Nelarabine label, warnings and precautionsConsideration should be given to the use of allopurinol in patients at risk of hyperuricemia [see Dosage and Administration ( 2.4 )].
Source: FDA drug label (Arranon), Sandoz Inc, effective March 31, 2025 (SPL set 0f9051de-5c4d-4c0f-8c19-e15214498cca), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Allopurinol | Nelarabine | |
|---|---|---|
| Labeled for | Gout | Leukemia, lymphoma and myeloma |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.0315 per tablet 100 mg tablet | n/a |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once